Robert A. Beckman

The paper develops a probability distribution for rare subclones in cancer and applies it to simulate dynamic precision medicine to improve treatment outcomes despite sequencing limitations.

This study enhances a personalized cancer treatment strategy by incorporating both irreversible and reversible drug resistance mechanisms, showing improved patient outcomes compared to current approaches.

CDGnet recommends targeted cancer therapies using a network approach that integrates biological pathway information and patient-specific molecular data.